journal
MENU ▼
Read by QxMD icon Read
search

Immunotherapy

journal
https://www.readbyqxmd.com/read/28771105/nk-92-cell-another-ideal-carrier-for-chimeric-antigen-receptor
#1
Wan-Ning Wang, Guang-Yu Zhou, Wen-Long Zhang
The remarkable clinical outcomes of the treatment for B-cell malignancies through the application of CD19 chimeric antigen receptor T (CAR-T) cells have made adoptive immunotherapy with genetically modified immune effector cells a hotspot in the field of antitumor. However, numerous toxicities of CAR-T cells have been identified. Thus, some studies have resorted to another cytotoxic cell, NK-92 cell, to reach for better efficacy with minimal toxicity. Preclinical studies have confirmed the safety and feasibility of the genetically modified NK-92 cells with highly specific cytotoxicity in vitro and in vivo...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771104/-atypical-car-t-cells-nkg2d-and-erb-b-as-examples-of-natural-receptor-ligands-to-target-recalcitrant-solid-tumors
#2
David E Gilham, John Maher
Chimeric antigen receptor (CAR) T-cell therapy has recently been recommended for approval for certain B-cell malignancies bringing the approach closer to mainstream cancer treatment. This rapid rise to prominence has been driven by impressive clinical results and the means to successfully commercialize the approach now being actively pursued. The current success of CAR T cells in B-cell malignancies relies upon the absolute lineage specificity of the CD19 antigen. CARs can also be targeted using non-antibody approaches, including the use of receptors and ligands to provide target specificity that have different specificities and binding kinetics...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771103/overcoming-barriers-of-car-t-cell-therapy-in-patients-with-mesothelin-expressing-cancers
#3
Mark H O'Hara, Caitlin Stashwick, Gabriela Plesa, Janos L Tanyi
One obstacle to the application of immunotherapy to solid malignancies is to overcome the existing tolerance to self-antigens. Vaccine strategies aimed at harnessing endogenous antitumor T cells are limited by the T-cell receptor repertoire, which can be detected within the thymus as central tolerance or rendered nonfunctional by post-thymic mechanisms of peripheral tolerance. Adoptive immunotherapy can overcome these obstacles, since therapeutically effective T cells can be engineered to recognize tumors. Continued advancements in novel treatments, including immunotherapy, in solid malignancies are imperative...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771102/convergence-of-immunotherapy-radiotherapy-and-prostate-cancer-challenges-and-opportunities
#4
Michael Green, Felix Y Feng, Rohit Mehra, Daniel E Spratt
No abstract text is available yet for this article.
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771101/natural-helper-cells-mediate-respiratory-syncytial-virus-induced-airway-inflammation-by-producing-type-2-cytokines-in-an-il-33-dependent-manner
#5
Xu Han, Ruonan Chai, Feifei Qi, Song Bai, Yulin Cui, Yuee Teng, Beixing Liu
AIM: Type 2 cytokine production during respiratory virus infection is considered to be linked with asthma exacerbation. As potent Th2 cytokine producers, natural helper (NH) cells play a key role in influenza virus-induced airway hyper-responsiveness. However, it is unclear whether NH cells contribute to respiratory syncytial virus (RSV)-induced airway inflammation, and how the cytokine profile in NH cells is changed during RSV infection. METHODS: BALB/c mice were infected intranasally with RSV...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771100/rare-transformation-to-double-hit-lymphoma-in-waldenstrom-s-macroglobulinemia
#6
Onyemaechi N Okolo, Ariel C Johnson, Seongseok Yun, Stacy J Arnold, Faiz Anwer
Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which bodes a poor prognosis. When transformation includes mutations of MYC, BCL-2 and/or BCL-6, it is known as a 'double hit' or 'triple hit' lymphoma respectively. This paper presents a rare case of WM with mutations positive for MYC and BCL2, making it a case of double hit B-cell lymphoplasmacytic lymphoma with plasmatic differentiation without morphological transformation to aggressive histology like DLBCL...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28771099/stabilizing-human-regulatory-t-cells-for-tolerance-inducing-immunotherapy
#7
Xuehui He, Hans Jpm Koenen, Jeroen Hr Slaats, Irma Joosten
Many autoimmune diseases develop as a consequence of an altered balance between autoreactive immune cells and suppressive FOXP3(+) Treg. Restoring this balance through amplification of Treg represents a promising strategy to treat disease. However, FOXP3(+) Treg might become unstable especially under certain inflammatory conditions, and might transform into proinflammatory cytokine-producing cells. The issue of heterogeneity and instability of Treg has caused considerable debate in the field and has important implications for Treg-based immunotherapy...
August 3, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28649876/myasthenia-gravis-induced-by-nivolumab-in-patients-with-non-small-cell-lung-cancer-a-case-report-and-literature-review
#8
Yoshikazu Hasegawa, Shigeru Kawai, Takayo Ota, Hiroshi Tsukuda, Masahiro Fukuoka
A 76-year-old woman who was diagnosed with non-small-cell lung cancer presented with left eyelid ptosis and grade 4 creatine phosphokinase elevation after the second cycle of nivolumab monotherapy. Nivolumab has demonstrated promising efficacy in patients with non-small-cell lung cancer in several trials. Dyspnea and muscle weakness developed rapidly with an acute exacerbation. She underwent plasmapheresis and intravenous immune globulin followed by treatment with low-dose prednisolone. She had gradual symptoms improvement...
June 26, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653575/evaluation-of-a-new-protocol-for-wheat-desensitization-in-patients-with-wheat-induced-anaphylaxis
#9
Mahsa Rekabi, Saba Arshi, Mohammad Hassan Bemanian, Vahab Rekabi, Abolfazl Rajabi, Morteza Fallahpour, Rasool Molatefi, Sima Shokri, Narges Eslami, Javad Ahmadian, Majid Khoshmirsafa, Farhad Seif, Seyed Alireza Mahdaviani, Nadieh Akbarpour, Mohammad Nabavi
AIM: New approaches such as oral immunotherapy (OIT) may be useful in IgE-mediated anaphylaxis to wheat. PATIENTS & METHODS: 12 patients underwent OIT protocol that comprised of two phases: the first with semolina flour and the second with spaghetti. Total and specific wheat IgE were assayed by ELISA before and after OIT and 18 months later. Skin prick tests were also performed. RESULTS: Patients successfully tolerated 50 g of wheat. The median baseline total IgE was decreased after up-dosing phase and decreased after follow-up (p < 0...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653574/combination-of-sorafenib-and-cytokine-induced-killer-cells-in-metastatic-renal-cell-carcinoma-a-potential-regimen
#10
Yonghao Yang, Hongwei Lin, Lingdi Zhao, Yongping Song, Quanli Gao
Metastatic renal cell carcinoma (MRCC) exhibits primary resistance to both chemotherapy and radiotherapy. As an immunogenic cancer, MRCC is relatively sensitive to immunotherapy such as that with cytokines, immune checkpoint inhibitors and adoptive T-cell therapy. In addition, many targeted agents developed over the past decade exhibit greater efficacy than cytokines and have become the standard first-line therapy for MRCC. Several preclinical studies have shown that the targeted agent sorafenib possesses an immunomodulation function and may be suitable for combination with immunotherapy...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653573/the-future-of-immune-checkpoint-cancer-therapy-after-pd-1-and-ctla-4
#11
Andrew W Hahn, David M Gill, Sumanta K Pal, Neeraj Agarwal
The adaptive immune system plays an important role in eradicating malignant cells. Co-stimulatory and co-inhibitory signals to T cells though immune checkpoint receptors are involved in tumorigenesis and metastasis. Exploitation of immune checkpoint inhibitors, PD-1 and CTLA-4, with monoclonal antibodies has created impressive clinical responses. Many other immune checkpoint co-inhibitors and co-stimulators exist, including the B7 superfamily and tumor necrosis factor receptors superfamily. Here, we will examine co-inhibitors and co-stimulators beyond PD-1 and CTLA-4 that are being investigated in active clinical trials...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653572/regulatory-t-cells-as-a-target-in-anticancer-immunotherapy
#12
Tomohiro Enokida, Hiroyoshi Nishikawa
No abstract text is available yet for this article.
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653571/chimeric-antigen-receptor-t-cells-for-the-treatment-of-cancer-and-the-future-of-preclinical-models-for-predicting-their-toxicities
#13
Anja Wegner
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical trials, particularly in B-cell malignancies. However, reports of serious adverse events including a number of patient deaths have raised concerns about safety of this treatment. Presently available preclinical models are not designed for predicting toxicities seen in human patients. Besides choosing the right animal model, careful considerations must be taken in chimeric antigen receptor T-cell design and the amount of T cells infused...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653570/the-second-wave-of-immune-checkpoint-inhibitor-tsunami-advance-challenges-and-perspectives
#14
Hampig Raphael Kourie, Gil Awada, Ahmad Awada
After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death protein 1 and anti-PDL1 approved by the FDA, the positive clinical trials published and the abstracts reported at important scientific meetings during 2016. Then, we highlighted the updates on debatable issues related to checkpoint inhibitors, since the first wave published in a previous issue...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653569/the-mutable-vaccine-for-mutable-viruses
#15
Marilia Cascalho, Samuel J Balin, Jeffrey L Platt
Mutable viruses, such as HIV, pose difficult obstacles to prevention and/or control by vaccination. Mutable viruses rapidly diversify in populations and in individuals, impeding development of effective vaccines. We devised the 'mutable vaccine' to appropriate the properties of mutable viruses that undermine conventional strategies. The vaccine consists of a DNA construct encoding viral antigen and regulatory sequences that upon delivery to B cells target the enzymatic apparatus of 'somatic hypermutation' causing the construct to mutate one million-times baseline rates and allowing production and presentation of antigen variants...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653568/time-to-leave-rigid-traditions-in-type-1-diabetes-research
#16
Johnny Ludvigsson
No abstract text is available yet for this article.
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28595520/a-case-of-fulminant-type-1-diabetes-following-anti-pd1-immunotherapy-in-a-genetically-susceptible-patient
#17
Manuel Araújo, Dário Ligeiro, Luís Costa, Filipa Marques, Helder Trindade, José Manuel Correia, Candida Fonseca
Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fulminant Type 1 diabetes induced by treatment with anti-programmed cell death-1 monoclonal antibody, nivolumab, in a patient with late-stage non-small-cell lung adenocarcinoma. The patient had no history of previous diabetes but did reveal a high-risk genotype for Type 1 diabetes development (DR3-DQ2; DR4-DQ8)...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28595519/t-cell-associated-immunotherapy-a-promising-strategy-for-the-treatment-of-hepatocellular-carcinoma
#18
Weijie Ma, Xi Chen, Yufeng Yuan
No abstract text is available yet for this article.
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28595518/humanization-of-chimeric-anti-cd20-antibody-by-logical-and-bioinformatics-approach-with-retention-of-biological-activity
#19
Yoke L Khoo, Swee H Cheah, Heilly Chong
AIM: To develop a fully bioactive humanized antibody from the chimeric rituximab for potential clinical applications using a relatively simpler and faster logical and bioinformatics approach. METHODS: From bioinformatics data, mismatched mouse amino acids in variable light and heavy chain amphipathic regions were identified and substituted with those common to human antibody framework. Appropriate synthetic DNA sequences inserted into vectors were transfected into HEK293 cells to produce the humanized antibody...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28595517/immunotherapy-for-pancreatic-cancer-present-and-future
#20
Francesca Aroldi, Alberto Zaniboni
Despite the identification of some efficient drugs for the treatment of metastatic pancreatic cancer, this tumor remains one of the most lethal cancers and is characterized by a strong resistance to therapies. Pancreatic cancer has some unique features including the presence of a microenvironment filled with immunosuppressive mediators and a dense stroma, which is both a physical barrier to drug penetration and a dynamic entity involved in immune system control. Therefore, the immune system has been hypothesized to play an important role in pancreatic cancer...
June 2017: Immunotherapy
journal
journal
42164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"